Buqué Aitziber, Bloy Norma, Aranda Fernando, Castoldi Francesca, Eggermont Alexander, Cremer Isabelle, Fridman Wolf Hervé, Fucikova Jitka, Galon Jérôme, Marabelle Aurélien, Spisek Radek, Tartour Eric, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo
Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM , U1138; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers ; Paris, France.
Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM , U1138; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers ; Paris, France ; Faculté de Medicine, Université Paris Sud/Paris XI ; Le Kremlin-Bicêtre, France.
Oncoimmunology. 2015 Mar 2;4(4):e1008814. doi: 10.1080/2162402X.2015.1008814. eCollection 2015 Apr.
Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory disorders, immunomodulatory mAbs have recently been shown to constitute a potent therapeutic weapon against neoplastic conditions. One class of immunomodulatory mAbs operates by inhibiting safeguard systems that are frequently harnessed by cancer cells to establish immunological tolerance, the so-called "immune checkpoints." No less than 3 checkpoint-blocking mAbs have been approved worldwide for use in oncological indications, 2 of which during the past 12 months. These molecules not only mediate single-agent clinical activity in patients affected by specific neoplasms, but also significantly boost the efficacy of several anticancer chemo-, radio- or immunotherapies. Here, we summarize recent advances in the development of checkpoint-blocking mAbs, as well as of immunomodulatory mAbs with distinct mechanisms of action.
免疫调节单克隆抗体（mAb）与其肿瘤靶向对应物不同，因为它们通过直接与免疫系统的可溶性或（最常见的）细胞成分相互作用来发挥治疗作用。除了有望用于治疗自身免疫性和炎性疾病外，免疫调节单克隆抗体最近还被证明是对抗肿瘤疾病的一种有效治疗武器。一类免疫调节单克隆抗体通过抑制癌细胞经常利用以建立免疫耐受的保护系统（即所谓的“免疫检查点”）来发挥作用。全球已批准不少于3种检查点阻断单克隆抗体用于肿瘤适应症，其中2种是在过去12个月内批准的。这些分子不仅在受特定肿瘤影响的患者中介导单药临床活性，而且还显著提高了几种抗癌化学疗法、放射疗法或免疫疗法的疗效。在此，我们总结了检查点阻断单克隆抗体以及具有不同作用机制的免疫调节单克隆抗体在开发方面的最新进展。
